The FDA has accelerated its review of Novartis’ sickle cell drug crizanlizumab after the company filed phase 2 results showing its effectiveness as a treatment for life threatening and pain
Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis drugs, where the big US pharma will pay $3.95 billion up front and
Another Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end two pivotal studies involving a medicine targeting BACE.
